Filing Flows

Filing Flows › 8-K events › Rapport Therapeutics

Rapport Therapeutics: entry into a material definitive agreement

Form 8-K filed Oct 30, 2026 · items 1.01, 2.02, 2.03, 3.02

What the filing says

Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants On October 28, 2026, Rapport Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan Stanley & Co.

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.02: +0.2% next session across 69,115. Item 2.03: 0.0% next session across 13,268. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Rapport Therapeutics at a glance

Latest quarterQ1 2026
Revenue$20.0M
Operating margin-121.1%
IndustryPharmaceutical Preparations

Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%. The chart follows the revenue to costs, profit and cash.

Rapport Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.